FDA Drug Approvals, Newly Elected Board of Directors, and Stock Price Updates on Healthcare Companies - Research Report on

FDA Drug Approvals, Newly Elected Board of Directors, and Stock Price Updates
on Healthcare Companies - Research Report on Theravance, Quintiles, Ironwood,
                         Progenics, and Immunomedics

PR Newswire

NEW YORK, December 25, 2013

NEW YORK, December 25, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Theravance
Inc. (NASDAQ: THRX), Quintiles Transnational Holdings Inc. (NYSE: Q), Ironwood
Pharmaceuticals Inc. (NASDAQ: IRWD), Progenics Pharmaceuticals Inc. (NASDAQ:
PGNX) and Immunomedics Inc. (NASDAQ: IMMU). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Theravance Inc. Research Report

On December 18, 2013, Theravance Inc. (Theravance), along with
GlaxoSmithKline, announced that the US Food and Drug Administration (FDA) has
approved ANORO ELLIPTA as a combination anticholinergic/long-acting
beta2-adrenergic agonist (LABA) indicated for the long-term, once-daily,
maintenance treatment of airflow obstruction in patients with chronic
obstructive pulmonary disease (COPD), including chronic bronchitis and/or
emphysema. The Company stated that Anoro Ellipta is the first once-daily
product approved in the US that combines two long-acting bronchodilators in a
single inhaler for the maintenance treatment of COPD, and is not indicated for
the relief of acute bronchospasm or for the treatment of asthma. Commenting on
the approval, Rick E. Winningham, CEO of Theravance said, "We are very pleased
that Anoro Ellipta has become the first once-daily dual bronchodilator
approved in the US for the treatment of COPD. This is a significant milestone
for Theravance and GSK and is testament to our ongoing partnership and shared
commitment to the development of respiratory medicines." The Full Research
Report on Theravance Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/fa70_THRX

--

Quintiles Transnational Holdings Inc. Research Report

On December 17, 2013, Quintiles Transnational Holdings Inc. (Quintiles)
announced the election of Mr. Richard Relyea to its Board of Directors. The
Company stated that Relyea was designated by equity investor 3i to fill a
vacancy on its Board of Directors, and came as the result of Denis Ribon's
pending departure from 3i and resulting resignation from the Quintiles board.
Pursuant to the Quintiles shareholders agreement, 3i retains the right to
designate a replacement to the board. The Company also mentioned that prior to
the Quintiles IPO, Relyea served as 3i's observer to the Quintiles board. The
Full Research Report on Quintiles Transnational Holdings Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/9f5c_Q

--

Ironwood Pharmaceuticals Inc. Research Report

On December 20, 2013, Ironwood Pharmaceuticals Inc.'s (Ironwood
Pharmaceuticals) stock rose 4.63%, ending the day at $11.76. Over the previous
three trading sessions, shares of Ironwood Pharmaceuticals gained 10.11%
compared to the Nasdaq Composite which gained 2.01% during the same period.
The Full Research Report on Ironwood Pharmaceuticals Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/dbc4_IRWD

--

Progenics Pharmaceuticals Inc. Research Report

On December 20, 2013, Progenics Pharmaceuticals Inc.'s (Progenics
Pharmaceuticals) stock rose 4.87%, ending the day at $5.17. Over the previous
three trading sessions, shares of Progenics Pharmaceuticals increased 12.64%,
significantly beating the Nasdaq Composite which increased 2.01% during the
same period. The Full Research Report on Progenics Pharmaceuticals Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/ce17_PGNX

--

Immunomedics Inc. Research Report

On December 20, 2013, Immunomedics Inc.'s (Immunomedics) stock rose 3.38%,
ending the day at $4.28. Over the previous three trading sessions, shares of
Immunomedics increased 4.90% compared to the Nasdaq Composite which increased
2.01% during the same period. The Full Research Report on Immunomedics Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/c20d_IMMU

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.